MINI3: "Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"

Sponsor
Humanitas Clinical and Research Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04934943
Collaborator
(none)
45
2
10.3
22.5
2.2

Study Details

Study Description

Brief Summary

The mini fluid challenge (mini_FC) is a functional hemodynamic test which has been used in different clinical contexts to assess fluid responsiveness.

This test is performed by rapidly injecting a small aliquot of fluid (100 ml over 1 minute), which is followed by the infusion of the residual aliquot of fluid.

Since the threshold of the mini_FC identified by the literature is rather small (5% of stroke volume (SV) increase after the 100 ml bolus to discriminate between responder and non-responder), it is crucial that the hemodynamic tool assessing this change could be reliable. Moreover, the SV changes with inspiratory/expiratory movements and the increase after the mini_FC should also consider the physiological fluctuations of the SV.

In the literature this test has been performed by means of tolls with different least significant change of the SV. The least significant change (LSC) represents the smallest difference between successive measurements of SV that can be considered to be a real change and not attributable to chance.

The purpose of this study is to assess the agreement among MOSTCARE system (4.5& of SV LSC described in the literature) and the echocardiography (about 10% of SV LSC described in the literature) with the PICCO system (about 1% of SV LSC described in the literature - considered the gold standard) in discriminating fluid responsiveness after a mini_FC

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: mini_FC

Detailed Description

Targeted fluid therapy has received increasing attention in the management of patients showing acute circulatory failure in both intensive care unit (ICU) and operating room (OR), aiming at preventing both inadequate tissue blood flow and fluid overload. In fact, unnecessary fluid administration can increase morbidity and mortality and length of hospital stay of critically ill and surgical patients.

Since the only physiological reason to give a fluid challenge (FC) is to increase the stroke volume (SV) and this effect is obtained only in about 50% of ICU and OR patients, a vast literature investigated the possibility of predict this effect before FC administration, but the issue remains extremely challenging. Bedside clinical signs and pressure and static volumetric static variables, do not predict fluid responsiveness. Moreover, several physiological factors affect the reliability of the ventilator-induced dynamic changes in pulse pressure and stroke volume [pulse pressure variation (PPV) and stroke volume (SV) variation (SVV), respectively], and their echographic surrogates, in a significant number of ICU and OR patients.

To overcome these limitations, the functional hemodynamic assessment (i.e. the assessment of the dynamic interactions of hemodynamic variables in response to a defined perturbation), of fluid responsiveness has gained in popularity. A functional hemodynamic test (FHT) consist in a manoeuvre determining a sudden change in cardiac function and/or heart lung interaction, affecting the hemodynamics of fluid responders and non-responders to a different extent.

The FHT called passive leg raising (PLR) has been successfully used for assessing the fluid responsiveness in ICU patients since 2009 and its reliability has been confirmed by three large meta-analyses. However, the PLR is not usually practicable in the OR.

A lot of different FHTs have been proposed, as alternative to the PLR, in ICU and, more recently, OR. These tests could be basically subdivided in two groups. A subgroup of FHTs is based on sudden and brief variations of the mechanical ventilation to induce a change in right ventricle preload and/or after load and, as consequence, of left ventricle. Among these tests, the rapid administration of a small aliquot of the predefined FC (the so-called mini FC) has gained in popularity in the last years.

On of the drawbacks of this test is that the optimal threshold identified in the literature to stratify responders and non-responders (5% of SV variation) is quite small, and potentially affected by the reliability of the hemodynamic tool used. The aim of this paper is to compare the reliability of a hemodynamic invasive tool (the (PiCCO2 TM, Pulsion Medical Systems, Munich, Germany - considered the gold standard) with a mini-invasive tool (MostCareTM system (Vytech Health, Padua, Italy) and a non-invasive (echocardiography) in predicting the response to the mini-FC in critically ill patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
45 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
"Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
Actual Study Start Date :
Oct 22, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Intervention _mini_FC

The fluid challenge consists of 4 ml*Kg of Crystalloids' solution infused over 10 minutes, administered via either a central or a peripheral line. The patient is already connected to the PICCO monitoring for clinical purpose of hemodynamic monitoring (before study enrollment) The MOSTCARE system is connected to the MONITOR of the patient (and not to the patient itself) by means of a cable inserted into the connections system. The echocardiography will be performed by a senior intensivist/cardiologist. The stroke volume is calculated by measuring VTI and diameter at the same point. This is best performed by measuring the diameter of the LVOT in the parasternal long axis (PLAX) view

Diagnostic Test: mini_FC
100 ml of Crystalloids infused over 1 minute - data recording and new baseline - FC 4 ml/kg in 10 minutes - data recording

Outcome Measures

Primary Outcome Measures

  1. Agreement of allocation [immediately after the procedure]

    Number of responders and non-responders identified by the MOSTCARE and the Echocardiography with respect to the PICCO system (considered as gold standard)

Secondary Outcome Measures

  1. Least significant change of the stroke volume - PICCO [5 minutes before FC administration]

    off-line analysis of the recorded stroke volume change before the test

  2. Least significant change of the stroke volume - MOSTCARE [5 minutes before FC administration]

    off-line analysis of the recorded stroke volume change before the test

  3. Least significant change of the stroke volume - Echocardiography [5 minutes before FC administration]

    off-line analysis of the recorded stroke volume change before the test

  4. ROC curve - PICCO [1 minute after mini fluid challenge infusion]

    ROC curve analysis of stroke volume changes after mini fluid challenge infusion

  5. ROC curve - MOSTCARE [1 minute after mini fluid challenge infusion]

    ROC curve analysis of stroke volume changes after mini fluid challenge infusion

  6. ROC curve - Echocardiograhy [1 minute after mini fluid challenge infusion]

    ROC curve analysis of stroke volume changes after mini fluid challenge infusion

  7. Agreement stroke volume estimation - MOSTCARE versus PICCO [immediately after the procedure]

    Agreements between stroke volume data are determined using the Bland-Altman method, with the bias calculated as the mean difference between methods and reflecting the measurement error between the two tests.

  8. Agreement stroke volume estimation - Echocardiography versus PICCO [immediately after the procedure]

    Agreements between stroke volume data are determined using the Bland-Altman method, with the bias calculated as the mean difference between methods and reflecting the measurement error between the two tests.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All

Inclusion criteria

  1. Acute circulatory failure defined as:
  • SAP ≤ 90 mmHg (or a decrease > 50 mm Hg in hypertensive patients)

  • or a mean arterial pressure (MAP) ≤ 70 mmHg

  • or the use of vasopressors to maintain SAP >90 mmHg,

  • associated with skin mottling; tachycardia ≥100 beats/min; urinary flow ≤0.5 mL/kg for at least 2 hours; blood lactate level ≥4 mmol/L.

Exclusion criteria:
  • known severe myocardial or valvular dysfunction

  • cardiac arrhythmias

  • severe acute respiratory distress syndrome

  • on-going haemodialysis or continuous hemofiltration

  • moribund patients

  • persistent low quality of the arterial signal affecting hemodynamic monitoring measurements

  • poor echographic windows.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Humanitas Research Hospital Rozzano Milano Italy 20089
2 Antonio Messina Novara Italy 28100

Sponsors and Collaborators

  • Humanitas Clinical and Research Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Humanitas Clinical and Research Center
ClinicalTrials.gov Identifier:
NCT04934943
Other Study ID Numbers:
  • MINI3
First Posted:
Jun 22, 2021
Last Update Posted:
Nov 1, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Humanitas Clinical and Research Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 1, 2021